V
2.02
0.03 (1.51%)
| Penutupan Terdahulu | 1.99 |
| Buka | 1.95 |
| Jumlah Dagangan | 87,394 |
| Purata Dagangan (3B) | 1,662,368 |
| Modal Pasaran | 5,268,083 |
| Harga / Pendapatan (P/E TTM) | 1.15 |
| Harga / Jualan (P/S) | 30.76 |
| Harga / Buku (P/B) | 1.10 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 4 Aug 2025 - 8 Aug 2025 |
| Margin Operasi (TTM) | -6,184.31% |
| EPS Cair (TTM) | -1.70 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 75.90% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 8.98% |
| Nisbah Semasa (MRQ) | 3.25 |
| Aliran Tunai Operasi (OCF TTM) | -9.46 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -5.03 M |
| Pulangan Atas Aset (ROA TTM) | -75.10% |
| Pulangan Atas Ekuiti (ROE TTM) | -35.31% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | VivoSim Labs, Inc. | - | - |
AISkor Stockmoo
0.5
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Purata | 0.50 |
|
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 1.00% |
| % Dimiliki oleh Institusi | 6.52% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 29 Jan 2026 | Pengumuman | VivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and China |
| 06 Jan 2026 | Pengumuman | VivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific Officer |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |